Form 4: Fulcrum Therapeutics Director Granted 36,000 Stock Options
Insider Transaction Report
Fulcrum Therapeutics, Inc. Director James A. Geraghty was granted 36,000 stock options with an exercise price of $7.38 per share, vesting over one year.
Summary
- Director James A. Geraghty of Fulcrum Therapeutics, Inc. (FULC) was granted 36,000 stock options.
- The options have an exercise price of $7.38 per share.
- The grant date for these options was June 26, 2025.
- The options are scheduled to vest with respect to all shares on the first anniversary of the grant date (June 26, 2026) or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
- The expiration date for these stock options is June 25, 2035.
Sentiment
Score: 6
Explanation: The grant of stock options to a director is a standard compensation practice that aligns management interests with shareholders, generally viewed as a neutral to slightly positive event.
Positives
- The grant of stock options to Director James A. Geraghty aligns his financial interests with the long-term performance and shareholder value creation of Fulcrum Therapeutics, Inc.
Future Outlook
na
Industry Context
na
Related Party Transactions
- The grant of 36,000 stock options to Director James A. Geraghty constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.
Stakeholder Impact
- Shareholders: Potential for minor future dilution if options are exercised, but also benefit from increased alignment of director's interests with company performance.
- Director (James A. Geraghty): Receives equity-based compensation, increasing his stake in the company and incentivizing long-term value creation.
Next Steps
- The stock options are scheduled to vest on the first anniversary of the grant date (June 26, 2026) or earlier, subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 06/26/2025 | Date of stock option grant to Director James A. Geraghty. |
| 06/30/2025 | Date the Form 4 was signed by the attorney-in-fact for James A. Geraghty. |
| 06/26/2026 | Scheduled vesting date for all granted stock options (first anniversary of grant date). |
| 06/25/2035 | Expiration date of the granted stock options. |
Keywords
Fulcrum Therapeutics, FULC, Stock Option Grant, SEC Form 4, Insider Transaction, Director Compensation, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.